(NEW YORK) -- Pfizer is advancing Phase 2/3 clinical trials for young kids at lower doses than vaccines for adults, the pharmaceutical company announced Tuesday. Based on safety, efficacy and tolerability data from Pfizer's Phase 1 trial, the company will use 10 micrograms of each... Read More.
Latest Local News
Everett Community Colleges Returns to In-Person Learning and Services
Everett Community College continues to grow and expand serving ...